Cargando…

Nintedanib plus Docetaxel after Immune Checkpoint Inhibitor Failure in Patients with Advanced Non-Small-Cell Lung Cancer: A Case Series

Advances in the treatment of non-small-cell lung cancers (NSCLCs) lacking an actionable driver mutation have included the approval of immunotherapies, such as monotherapy or in combination with chemotherapy. However, limited evidence exists to guide clinical decision-making after progression with im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hochmair, Maximilian Johannes, Kolb, Rainer, Wurm, Robert, Zach, Herwig, Bittner, Nora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921945/ https://www.ncbi.nlm.nih.gov/pubmed/35350799 http://dx.doi.org/10.1159/000520939

Ejemplares similares

Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC
por: Westeel, Virginie, et al.
Publicado: (2023)

Successful treatment with docetaxel plus nintedanib in a patient with lung adenocarcinoma and pulmonary fibrosis: A case report and literature review
por: Zlatanova, Tanya, et al.
Publicado: (2022)

Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO
por: Grohé, Christian, et al.
Publicado: (2022)

Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study
por: Reck, Martin, et al.
Publicado: (2018)

Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study
por: Korphaisarn, Krittiya, et al.
Publicado: (2021)

An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy
por: Yamamoto, Noboru, et al.
Publicado: (2018)

Safety of nintedanib before lung transplant: an Italian case series
por: Balestro, Elisabetta, et al.
Publicado: (2018)

Resistance to chemoimmunotherapy in non-small-cell lung cancer
por: Hochmair, Maximilian Johannes
Publicado: (2020)

Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib
por: Lin, Tong, et al.
Publicado: (2017)

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
por: Wollin, Lutz, et al.
Publicado: (2015)

Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
por: Ma, Zehua, et al.
Publicado: (2022)

Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review
por: Pan, Lei, et al.
Publicado: (2023)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
por: Bianchini, Giampaolo, et al.
Publicado: (2017)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV
por: Brueckl, Wolfgang M, et al.
Publicado: (2020)

Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV
por: Brueckl, Wolfgang M., et al.
Publicado: (2021)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma
por: Rodríguez-Cid, Jeronimo Rafael, et al.
Publicado: (2020)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
por: Huang, Jin-Tao, et al.
Publicado: (2022)

Radiotherapy plus immune checkpoint inhibitor in prostate cancer
por: Li, Tianjie, et al.
Publicado: (2023)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer Types
por: Robinson, Irina, et al.
Publicado: (2023)

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
por: Flaherty, Kevin R., et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
por: Wind, Sven, et al.
Publicado: (2019)

Bullous pemphigoid associated with nintedanib
por: Hasson, Amelia M., et al.
Publicado: (2019)

Experience With Nintedanib in Severe Pulmonary Fibrosis Associated With Systemic Sclerosis: A Case Series
por: Bordas-Martinez, Jaume, et al.
Publicado: (2021)

Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis
por: Ljubicic, Lidija, et al.
Publicado: (2023)

Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ang, et al.
Publicado: (2017)

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure
por: Bonneterre, J, et al.
Publicado: (2002)

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2021)

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
por: Shiono, Ayako, et al.
Publicado: (2019)

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
por: Rosenberg, Jonathan E., et al.
Publicado: (2018)

Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
por: Noth, Imre, et al.
Publicado: (2019)

The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease
por: Jamadar, Abeda, et al.
Publicado: (2021)

Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics
por: Kolb, Martin, et al.
Publicado: (2023)

A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
por: Lee, Keun-Wook, et al.
Publicado: (2017)

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
por: Tebbutt, N C, et al.
Publicado: (2013)

Focus on Nintedanib in NSCLC and Other Tumors
por: Manzo, Anna, et al.
Publicado: (2016)

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
por: Marzin, Kristell, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f97tpcr8oki1lpen0e08k5kp65